Advertisement

Topics

ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer

02:59 EDT 10 Sep 2017 | ecancermedicalscience

The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid, showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone...

Original Article: ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer

NEXT ARTICLE

More From BioPortfolio on "ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer"

Quick Search
Advertisement
 

Relevant Topics

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...